TY  - BOOK
AU  - Badr, Salem
AU  - Barbash, Israel M
AU  - Ben-Dor, Itsik
AU  - Loh, Joshua P
AU  - Minha, Sa'ar
AU  - Pichard, Augusto D
AU  - Satler, Lowell F
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice
SN  - 1042-3931
PY  - 2014///
KW  - *Coronary Artery Disease/th [Therapy]
KW  - *Drug-Eluting Stents
KW  - *Percutaneous Coronary Intervention/is [Instrumentation]
KW  - *Percutaneous Coronary Intervention/mt [Methods]
KW  - *Postoperative Complications/ep [Epidemiology]
KW  - *Sirolimus/aa [Analogs & Derivatives]
KW  - Aged
KW  - Coronary Stenosis/ep [Epidemiology]
KW  - Coronary Stenosis/et [Etiology]
KW  - Drug-Eluting Stents/ae [Adverse Effects]
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Incidence
KW  - Longitudinal Studies
KW  - Male
KW  - Middle Aged
KW  - Myocardial Infarction/ep [Epidemiology]
KW  - Myocardial Infarction/et [Etiology]
KW  - Paclitaxel
KW  - Postoperative Complications/et [Etiology]
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Comparative Study
KW  - Journal Article
KW  - Observational Study
N1  - Available online from MWHC library: 2001 - present, Available in print through MWHC library: 2003 - 2008
N2  - BACKGROUND: There are limited long-term data comparing Xience V EES vs the first-generation Cypher SES; CONCLUSIONS: In a contemporary clinical United States practice with an unselected patient population, Xience V EES use was associated with improved safety profile and reduction of all-cause mortality and stent thrombosis when compared to both first-generation drug-eluting stents. This superiority continues to widen from 1 to 2 years; METHODS: This retrospective analysis included 6069 patients treated with Cypher SES, Taxus PES, or Xience V EES from 2003-2009 at our institution. Patients were followed by telephone contact or office visit up to 2 years after the index procedure; OBJECTIVE: This study aimed to assess the long-term safety and clinical effectiveness of the Xience V everolimus-eluting stent (EES) compared to both Taxus paclitaxel-eluting stent (PES) and Cypher sirolimus-eluting stent (SES) in an unselected patient population; RESULTS: Baseline characteristics were generally comparable, with the exception of a significantly higher prevalence of diabetes mellitus, systemic hypertension, history of angioplasty, and coronary bypass surgery among Xience V EES patients. At 2 years, the incidence of major adverse cardiovascular events was 13.3% (Xience V EES) vs 17.8% (Cypher SES) vs 22% (Taxus PES) (P<.001). The main drivers for the differences in event rates were lower mortality, the need for target vessel revascularization, and Q-wave myocardial infarction. Stent thrombosis was lowest in Xience V EES patients (0.2% vs 1.2% SES vs 0.7% PES, respectively; P=.01). A landmark analysis after 1 year showed that the benefits of Xience V EES continued in long-term follow-up
ER  -